纳米光的竞争优势
我们的优势基于三个关键的专有位置:
获得新的生物发光和荧光蛋白质分子。
世界上成本最低的柯伦他嗪(纳米燃料)生产技术™), 发光所必需的。
世界上最大的海洋生物发光生物表达文库。NanoLight已经开发了这些专利技术,或受到专利申请和商业秘密的保护,这些专利技术使该公司能够成长为生命科学市场专有生物发光试剂和报告系统的主要供应商。NanoLight®可以立即让合作伙伴访问:
新的绿色荧光蛋白基因从古氏裂殖吸虫(Ptilosarcus gurneyi)和毛里氏雷尼拉(Renilla Mulleri)中分离出来,具有独特的特性,包括一个新的发色团序列,该序列与Aeqourea绿色荧光蛋白的6个残基中有3个不同。
新的海洋荧光素酶克隆自Renilla Mulleri、Pleuromama sp.和Gaussia sp.,后者似乎比哺乳动物细胞中现有的Renilla或萤火虫系统更亮。
生物发光蛋白在硅芯片上用于廉价高通量筛选和诊断应用的新用途正在申请专利。
来自超过四十(40)种不同发光生物体的cDNA文库,用于进一步的基因发现、专利和许可。
专有功能筛选方法,用于识别新的生物发光基因。
这一巨大的遗传资源代表着领先的生命科学公司竞相建立先进的高通量筛查和诊断系统的机会。
Nanolight® Technology is a biotechnology company developing broad applications of natural, light-emitting marine proteins, or marine bioluminescence. The NanoLight division is focused on becoming the leader in high-value reagent & reporter systems for new product development in the pharmaceutical, agrichemical, and research products industries.
Valuable life science uses for NanoLight®’s technology include high-throughput drug discovery, functional genomics, tumor imaging, replacement of radioisotopes, and molecular diagnostics. One particularly exciting application is the ability to use NanoLight®’s reporter systems to “illuminate” gene and molecular function within living cells, allowing pharmaceutical companies a revolutionary method to study drug activity. A second opportunity is to broadly supply researchers who are increasingly moving away from radioactive reagents toward light-based reporter systems and instruments. NanoLight® Technologies is poised to capitalize on both of these accelerating market trends.
NanoLight’s competitive advantage Our advantage is based on three crucial proprietary positions:
Access to the novel bioluminescent and fluorescent protein molecules. World’s lowest-cost production technology for coelenterazine (NanoFuel™), necessary for light emission. World’s largest collection of expression libraries from marine bioluminescent organisms.These proprietary technologies, which NanoLight has already developed or protected by patent filings & trade secrets, permit the company to grow into the dominant supplier of proprietary bioluminescent reagents and reporter systems to the life science markets. NanoLight® can immediately provide partners access to: Novel GFP genes isolated from Ptilosarcus gurneyi and Renilla Mulleri with distinctive properties including a novel chromophore sequence that differs in 3 of 6 residues from the Aequorea GFP. Novel marine luciferases cloned from Renilla Mulleri, Pleuromama sp., and Gaussia sp., the latter appears to be brighter than existing Renilla or Firefly systems in mammalian cells. Pending patents on the novel use of bioluminescent proteins on silicon chips for inexpensive high throughput screening and diagnostic applications. cDNA libraries from over forty (40) different luminescent organisms for further gene discovery patenting, and licensing. Proprietary functional screening methods to identify new bioluminescent genes. This enormous genetic resource represents an outstanding opportunity for leading life sciences companies racing to establish advanced high-throughput screening and diagnostic systems.